OR WAIT null SECS
May 16, 2026
Video
Fechner discusses the 2-year data from an open-label extension of the CAHtalyst Pediatric study, maintaining substantial glucocorticoid dose lowering.
April 30, 2026
Shahla discusses a recent real-world study analyzing the clinical outcomes of patients prescribed paltusotine after its September 2025 approval.
April 15, 2026
Bacino highlights the recently approved treatment’s safety data and emphasizes the likelihood of increased adherence due to longer intervals between administration.
January 01, 2026
Article
2025 featured multiple advancements in women's health aimed at enhancing treatment options and awareness.
December 30, 2025
Catch up on the most impactful headlines in hormonal disorders from all of 2025 with our Year in Review.
October 08, 2025
The Q3 recap for endocrinology spotlights major FDA decisions, new guidelines for managing diabetes during pregnancy, and major clinical trial updates.
October 07, 2025
Catch up on FDA decisions, critical trial results, and expert perspectives on endocrinology.
August 08, 2025
Discover key advancements in endocrinology from July 2025, including FDA approvals and trial results.
July 21, 2025
Presented at ENDO 2025, crinecerfont exhibited sustained androgen reduction when combined with glucocorticoids.
July 04, 2025
Explore key advancements in endocrinology from Q2 2025, including FDA approvals and groundbreaking diabetes research shaping future treatments.
